Cargando…

(18)F-FDG and (68)Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study

BACKGROUND: Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin tumor. Currently, (18)F-fluoro-deoxy-glucose ((18)F-FDG) PET/CT is the functional imaging modality of choice. Few data are available on the use of (68)Ga-somatostatin analogs. The aim of our study was to evaluate and compar...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taralli, Silvia, Sollini, Martina, Milella, Michele, Perotti, Germano, Filice, Angelina, Menga, Massimo, Versari, Annibale, Rufini, Vittoria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6054830/ https://www.ncbi.nlm.nih.gov/pubmed/30032450 http://dx.doi.org/10.1186/s13550-018-0423-3

Ejemplares similares

PET and PET/CT with (68)Gallium-Labeled Somatostatin Analogues in Non GEP-NETs Tumors
por: Sollini, Martina, et al.
Publicado: (2014)

Predictive and Prognostic Role of Pre-Therapy and Interim 68Ga-DOTATOC PET/CT Parameters in Metastatic Advanced Neuroendocrine Tumor Patients Treated with PRRT
por: Durmo, Rexhep, et al.
Publicado: (2022)

Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors
por: Ambrosini, Valentina, et al.
Publicado: (2022)

Impact of Cold Somatostatin Analog Administration on Somatostatin Receptor Imaging: A Systematic Review
por: Morland, David, et al.
Publicado: (2023)

The Influence of Long-Acting Somatostatin Analogs on (68)Ga-DOTATATE Uptake in Patients With Neuroendocrine Tumors
por: Chahid, Youssef, et al.
Publicado: (2023)

Highly variable biodistribution of (68)Ga labeled somatostatin analogues (68)Ga-DOTA-NOC and (68)Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT
por: Cheng, Monica, et al.
Publicado: (2022)

Radiolabeled Somatostatin Analogues Therapy in Advanced Neuroendocrine Tumors: A Single Centre Experience
por: Filice, A., et al.
Publicado: (2012)

A new (68)Ga-labeled somatostatin analog containing two iodo-amino acids for dual somatostatin receptor subtype 2 and 5 targeting
por: Mansi, Rosalba, et al.
Publicado: (2020)

The role of (68)Ga-DOTA derivatives PET-CT in patients with ectopic ACTH syndrome
por: Ceccato, Filippo, et al.
Publicado: (2020)

The Search for an Alternative to [(68)Ga]Ga-DOTA-TATE in Neuroendocrine Tumor Theranostics: Current State of (18)F-labeled Somatostatin Analog Development
por: Waldmann, Christopher M., et al.
Publicado: (2019)

Role of Combined [(68)Ga]Ga-DOTA-SST Analogues and [(18)F]FDG PET/CT in the Management of GEP-NENs: A Systematic Review
por: Carideo, Luciano, et al.
Publicado: (2019)

Preoperative (68)Ga-DOTA-Somatostatin Analog-PET/CT Hybrid Imaging Increases Detection Rate of Intra-abdominal Small Intestinal Neuroendocrine Tumor Lesions
por: Norlén, Olov, et al.
Publicado: (2017)

Correlation of Somatostatin Receptor 1–5 Expression, [(68)Ga]Ga-DOTANOC, [(18)F]F-FDG PET/CT and Clinical Outcome in a Prospective Cohort of Pancreatic Neuroendocrine Neoplasms
por: Majala, Susanna, et al.
Publicado: (2021)

Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma
por: Iglseder, Sarah, et al.
Publicado: (2023)

Somatostatin Receptors in Merkel-Cell Carcinoma: A Therapeutic Opportunity Using Somatostatin Analog Alone or in Association With Checkpoint Inhibitors Immunotherapy. A Case Report
por: Guida, Michele, et al.
Publicado: (2020)

Merkel Cell Carcinoma: Mind the Genital Metastatic Sites!
por: Santandrea, Giacomo, et al.
Publicado: (2023)

SAT-575 Radiolabeled Somatostatin Receptor Analog (86)Y-EB-TATE is Characterized by Superior Tumor Uptake Compared to (68)Ga-DOTA-TATE and (68)Ga-DOTA-JR11 in Thyroid Cancer Mice Models
por: Thakur, Shilpa, et al.
Publicado: (2019)

The impact of the COVID-19 pandemic on oncological disease extent at FDG PET/CT staging: the ONCOVIPET study
por: Caldarella, Carmelo, et al.
Publicado: (2021)

Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT
por: Oh, Sowon, et al.
Publicado: (2011)

Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors
por: Roden, Anja C., et al.
Publicado: (2022)

Detection of Atherosclerotic Inflammation by (68)Ga-DOTATATE PET Compared to [(18)F]FDG PET Imaging
por: Tarkin, Jason M., et al.
Publicado: (2017)

Ga-68-Edotreotide Positron Emission Tomography/Computed Tomography Somatostatin Receptors Tumor Volume Predicts Outcome in Patients With Primary Gastroenteropancreatic Neuroendocrine Tumors
por: Gallicchio, Rosj, et al.
Publicado: (2023)

(68)Ga-Chloride PET Reveals Human Pancreatic Adenocarcinoma Xenografts in Rats—Comparison with FDG
por: Ujula, Tiina, et al.
Publicado: (2009)

Comparison of (18)F-FDG PET/CT and (68)Ga-FAPI in Spindle Cell Rhabdomyosarcoma
por: Shen, Zhihui, et al.
Publicado: (2023)

What to Trust, PSA or [(68)Ga]Ga-PSMA-11: Learn from Experience
por: Viglialoro, Rita, et al.
Publicado: (2021)

Radiotherapy Planning and Molecular Imaging in Lung Cancer
por: Filice, Angelina, et al.
Publicado: (2020)

(68)Ga-DOTATOC PET/CT-Based Radiomic Analysis and PRRT Outcome: A Preliminary Evaluation Based on an Exploratory Radiomic Analysis on Two Patients
por: Liberini, Virginia, et al.
Publicado: (2021)

Affinity of (nat/68)Ga-Labelled Curcumin and Curcuminoid Complexes for β-Amyloid Plaques: Towards the Development of New Metal-Curcumin Based Radiotracers
por: Rubagotti, Sara, et al.
Publicado: (2016)

Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F]FDG PET/MRI in the Preoperative Diagnosis of Gastric Cancer
por: Du, Tao, et al.
Publicado: (2023)

(68)Ga-PSMA PET/CT Versus (18)F-FDG PET/CT for Imaging of Hepatocellular Carcinoma
por: Gündoğan, Cihan, et al.
Publicado: (2021)

[(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging
por: Hennrich, Ute, et al.
Publicado: (2020)

PET/CT with Fibroblast Activation Protein Inhibitors in Breast Cancer: Diagnostic and Theranostic Application—A Literature Review
por: Taralli, Silvia, et al.
Publicado: (2023)

(68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity
por: Chang, Chian A., et al.
Publicado: (2016)

Comparative Findings Between (68)Ga-PSMA and (18)F-FDG PET/CT for Hepatocellular Carcinoma
por: Erhamamcı, Seval, et al.
Publicado: (2020)

(68)Ga-FAPI-04 Versus (18)F-FDG PET/CT in the Detection of Hepatocellular Carcinoma
por: Wang, Hao, et al.
Publicado: (2021)

THU511 Somatostatin Analogs Or Active Surveillance In Sporadic And MEN1 Associated Non-functioning Pancreatic Neuroendocrine Tumors
por: Raia, Salvatore, et al.
Publicado: (2023)

Dual Tracer 68Ga-DOTATOC and 18F-FDG PET Improve Preoperative Evaluation of Aggressiveness in Resectable Pancreatic Neuroendocrine Neoplasms
por: Mapelli, Paola, et al.
Publicado: (2021)

Comparison of 99mTc radiolabeled somatostatin antagonist with [(68) Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
por: Opalinska, Marta, et al.
Publicado: (2023)

Comparison of [(68)Ga]Ga-DOTA-FAPI-04 and [(18)F]FDG Uptake in Esophageal Cancer
por: Liu, Huipan, et al.
Publicado: (2022)

Comparison of Diagnostic Efficacy of [(68)Ga]Ga-FAPI-04 and [(18)F]FDG PET/CT for Staging and Restaging of Gastric Cancer
por: Zhang, Shumao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_uvo4ei799hp5fpioccd2vetulg